Board Certified Cardiology Pharmacist (BCCP) Practice Exam

In the context of a patient experiencing right ventricular (RV) failure due to pulmonary arterial hypertension (PAH) and who has been stabilized with fluids, the use of inotropic agents as a second-line therapy is particularly appropriate.

Inotropic agents enhance myocardial contractility and can markedly improve cardiac output, which is essential in managing RV failure. They can help support the functioning of the right ventricle during periods of low contractility, thereby improving perfusion and reducing the symptoms of shock. This is especially crucial in patients with PAH, where the right ventricle often struggles to pump blood against elevated pressures in the pulmonary circulation. The use of inotropes can directly address these circulatory challenges and improve hemodynamic status.

Other treatment options, while valid in different contexts, may not provide the immediate or necessary support for RV function in this acute scenario. For instance, diuretics might address fluid overload but do not improve pumping efficiency of the RV, which is critical in the setting of RV failure due to PAH. Short-acting calcium channel blockers are sometimes used in PAH but are generally reserved for select patients with acute vasodilatory response, and they can lead to decreased systemic vascular resistance, which may not help a patient in